All articles by Hasini Devarasetti
Hasini Devarasetti
AstraZeneca reports positive data from lung cancer combo therapy trial
The Tagrisso and chemotherapy combination therapy showed strong improvement in progression-free survival.
MindMed completes 50% subject enrolment and dosing in GAD therapy trial
The trial will assess four MM-120 doses to treat anxiety symptoms in GAD diagnosed patients.
Indapta plans Phase I trial of NK Cell therapy
The trial will assess three different dose levels of G-NK cells alone and along with interleukin-2 and the monoclonal antibodies.
Phio Pharmaceuticals receives FDA IND clearance for PH-762 trial
The first Phase Ib trial will assess the tolerability and safety of neoadjuvant use of intratumorally injected PH-762.
Protara begins subject dosing in Phase Ib ADVANCED-1EXP expansion trial
The trial will assess the intravesical TARA-002 at the 40KE dose in 12 patients with CIS.
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
KinoPharma, IWAKI SEIYAKU start Phase II study of cutaneous warts drug
The trial will confirm the efficacy of the drug candidate for the treatment of cutaneous warts.
Mabwell reports positive clinical data of anti-Nectin-4 drug ADC 9MW2821
The preliminary data showed 50% objective response rate and 100% disease control rate in six cervical carcinoma patients.
Merck, Eisai decide to discontinue advanced melanoma therapy trial
The companies’ decision is based on the recommendation from an independent data monitoring committee (DMC).
FDA places partial hold on Molecular Templates’ Phase I trial
The company will not recruit new participants for the trial until the partial hold is lifted.
Doxycycline prevents acquisition of sexually transmitted infections in trial
The National Institute of Allergy and Infectious Diseases, part of the NIH, provided funding for the study.